Eventually, just published result from a phase 1 clinical trial suggested that rogaratinib, a novel kinase inbibitor of FGFR1-4, resulted in an encouraging objective response (15%) 11, if screened by FGFR mRNA overexpressing cancers, which compares favorably with the objective response observed with other selective pan-FGFR inhibitors in early clinical trials, such as AZD4547 (8%), infigratinib (BGJ398) (5%) 9, and Erdafitinib (JNJ-42756493) (11%) 34. This evidence concerns the gene FGFR1 and cancer.